Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028 Report Analysis & Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global Bispecific Antibodies Market Opportunity Assessment: > USD 20 Billion
- Market & Drug Sales Insight 2020 Till 2028
- Approved Drug Patent, Price & Sales insight 2020 Till 2028
- Commercially Available Bispecific Antibodies: 3 (Blincyto, Hemlibra) & Rybrevant
- Approved Bispecific Antibodies Dosage, Patent, Price, Yearly Sales, Quarterly Sales, Global and Regional Sales Insight
- Future Market Assessment Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
https://www.kuickresearch.com/report-global-bispecific-antibodies-antibody-market-size-blincyto-hemlibra-rybrevant-sales
With the advancement in the field of science and innovation, the healthcare facilities are continuously evolving achieving significant advances in cure rates and increasing patient survival. In recent times, the idea of harnessing the power of immune system in management of disease is gaining momentum in management of several chronic disorders. The advent of hybridoma technology has led to the development of monoclonal antibodies which have greatly revolutionized the paradigm of treatment.
Monoclonal antibodies have the ability to bind to single target which is critical in the progression of the disease. With the approval of first monoclonal antibody Orthoclone OKT3, there was race among the pharmaceutical giants for the development of novel antibodies which can be used in management of fatal diseases. Despite various advantages of the monoclonal antibodies, their role is restricted in some diseases due to their exceptionally large size which lead to poor penetration in the cell membrane. Moreover, the synthesis of monoclonal antibodies is highly complex and tedious.
However, the progress in technology has led to the development of their effective “bispecific” counterparts. Bispecific antibodies are emerging as a novel immunotherapeutic approach which is developed by combining two antigen-recognizing elements in single construct which can simultaneously bind two different targets. Their novel dual binding efficacy opens up a wide range of applications application which can be exploited in redirecting T-cells, blocking two different signaling pathways, dual targeting of different disease mediators and delivering payloads to targeted cells. Their unique ability along with the rapid progress in antibody engineering has prompted the research and development in this sector which has led to development of several bispecific formats.
Currently, only 3 bispecific antibodies including Hemlibra for Hemophilia, Blincyto for Leukemia and Rybrevant for metastatic NSCLC is present in the market. Their entrance in the market has greatly transformed the immunotherapeutic market. The bispecific antibodies hold a potential space in the overall immunotherapy market due to the robust sales of these drugs. The high clinical response and promising results has encouraged the research and development activities in his sector. Several bispecific antibodies are currently present in clinical trials which are expected to enter the market in next few years.
Pharmaceutical companies involved in the development of bispecific antibodies strongly believe that their products are superior to first generation therapeutic antibodies. In addition to this, the role of bispecific antibodies is not only confined to oncological use but also the non-oncological use which includes rejection of organ transplants, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough which will drive the market in coming years.
The considerable rise in the geriatric population along with shift towards sedentary lifestyle increases the risk of developing the diseases. Moreover, the unavailability of effectively curing drugs and the rate at which conventional therapies are failing possess an unmet need for the development of targeted therapies which will boost the growth of the market. In addition to this, the rising funding by the government as well as private sectors also increases the research and development activities in this area.
Currently, US hold the top position in the global bispecific antibody market which is mainly attributed to the rise in prevalence of the disease as well as huge spending on the healthcare. Moreover, the presence of large pharmaceutical giants in this region as well as rising partnerships and collaborations between them also favors extensive research activities in this region. In addition to this, Europe as well as Asia-Pacific is also expected to witness high growth in coming years due to various un-tapped opportunities in this region and the rising geriatric population which further increases the risk of developing the disease.
Contact:
Neeraj Chawla
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com